Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma

Table 3 Univariate and multivariate analyses for hepatocellular carcinoma recurrence after direct-acting antiviral treatment

Factors	Univariate			Multivariate
	HR	95% CI	P value	HR	95% CI	P value
Age	0.98	0.92-1.04	0.52
CH or LC	0.50	0.21-1.21	0.12
Diabetes	1.12	0.79-1.59	0.53
Habitual alcohol use	1.08	0.68-1.51	0.51
Fib-4	1.01	0.93-1.09	0.86
AFP at baseline	1.01	1.00-1.01	0.22
AFP at EOT	1.09	1.00-1.19	0.05	1.10	1.00-1.01	0.05
AFP at SVR	1.01	1.00-1.01	0.04	1.01	1.00-1.01	0.08
Duration between first HCC and DAAs treatment	1.00	1.00-1.00	0.18
Number of HCC occurrence	1.32	1.06-1.64	0.02	1.61	1.18-2.19	< 0.01

AFP: Alpha fetoprotein; CH: Chronic hepatitis; CI: Confidence interval; DAAs: Direct-acting antivirals; EOT: End of treatment; HCC: Hepatocellular carcinoma; HR: Hazard ratio; LC: Liver cirrhosis; SVR: Sustained viral response.